Your browser doesn't support javascript.
loading
Evaluation of histological variants of upper tract urothelial carcinoma as prognostic factor after radical nephroureterectomy.
Song, Byeongdo; Kim, Jung Kwon; Lee, Hakmin; Lee, Sangchul; Hong, Sung Kyu; Byun, Seok-Soo; Oh, Jong Jin.
Affiliation
  • Song B; Department of Urology, Hanyang University Guri Hospital, Guri, Kyunggi-Do, South Korea, 11923.
  • Kim JK; Department of Urology, Seoul National University Bundang Hospital, 300, Gumi-Dong, Bundang-Gu, Seongnam, Kyunggi-Do, South Korea, 13605.
  • Lee H; Department of Urology, Seoul National University College of Medicine, Seoul, South Korea.
  • Lee S; Department of Urology, Seoul National University Bundang Hospital, 300, Gumi-Dong, Bundang-Gu, Seongnam, Kyunggi-Do, South Korea, 13605.
  • Hong SK; Department of Urology, Seoul National University College of Medicine, Seoul, South Korea.
  • Byun SS; Department of Urology, Seoul National University Bundang Hospital, 300, Gumi-Dong, Bundang-Gu, Seongnam, Kyunggi-Do, South Korea, 13605.
  • Oh JJ; Department of Urology, Seoul National University College of Medicine, Seoul, South Korea.
World J Urol ; 42(1): 225, 2024 Apr 09.
Article in En | MEDLINE | ID: mdl-38592495
ABSTRACT

PURPOSE:

To evaluate the impact of variant histology on patients with upper tract urothelial carcinoma (UTUC) survival outcomes. MATERIALS AND

METHODS:

A total of 519 patients underwent radical nephroureterectomy without neoadjuvant therapy for UTUC at a single institution between May 2003 and December 2019. Multivariate Cox regression analysis evaluated the impact of variant histology on progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS).

RESULTS:

Among 84 patients (16.2%) with variant histology, the most frequent variant type was squamous cell differentiation (64.3%), followed by glandular differentiation (25.0%) and sarcomatoid variant (2.4%). They showed pathologically advanced T stage (for ≥ T3, 59.5% vs 33.3%, p < 0.001), higher tumor grade (96.4% vs 85.7%, p = 0.025), and higher rates of lymph node metastasis (17.9% vs 7.8%, p = 0.015), angiolymphatic invasion (41.7% vs 25.7%, p = 0.003), tumor necrosis (57.1% vs 29.0%, p < 0.001) and positive surgical margin (13.1% vs 5.7%, p = 0.015). On multivariate Cox regression analyses, variant histology was significantly associated with worse PFS (hazard ratio [HR] 2.23; 95% confidence interval [CI] 1.55-3.21; p < 0.001), CSS (HR 2.67; 95% CI 1.35-5.30; p = 0.005) and OS (HR 2.22; 95% CI 1.27-3.88; p = 0.005). In subgroup analysis, no significant survival gains of adjuvant chemotherapy occurred in patients with variant histology.

CONCLUSIONS:

Variant histology was associated with adverse pathologic features and poor survival outcomes. Our results suggest that patients with variant histology may require a close follow-up schedule and novel adjuvant therapy other than chemotherapy postoperatively.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell Limits: Humans Language: En Journal: World J Urol Year: 2024 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell Limits: Humans Language: En Journal: World J Urol Year: 2024 Type: Article